
MATERIALISE NV-ADR
MTLSNASDAQTrading Snapshot
- Day Range
- $6.85 β $6.95
- 52-Week Range
- β
- Volume
- $2.00B
- Avg Volume
- $2.10B
- Shares Outstanding
- 59.1M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $257M
- Last Q Revenue
- $66M
- P/E Ratio
- 78.9
- P/S Ratio
- 1.3x
- EPS (TTM)
- β
- Dividend Yield
- β
Why Investors Own MTLS
- βHigh-growth profile β revenue up +45.0% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MATERIALISE NV-ADR
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
MATERIALISE NV-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MTLS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MATERIALISE NV-ADR announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.